Tuesday, 27 October 2020
Dechra® Pharmaceuticals PLC
(Dechra, Group, Company)
Annual General Meeting
Trading update
The Board of Dechra issues the following statement prior to the Annual General Meeting (AGM) which will take place at the Company's offices at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA at 9.30 am today, Tuesday 27 October 2020:
Trading in the first quarter of the financial year has been stronger than expected however at this early stage of the year the ongoing effect of COVID-19 on our markets is not yet certain.
No other new trading updates are to be made at the AGM today.
Dechra will announce its interim results for the six month period to 31 December 2020 on 22 February 2021.
|
Enquiries:
|
|
Dechra Pharmaceuticals PLC
|
|
|
Ian Page, Chief Executive Officer
|
Office: +44 (0) 1606 814 730
|
|
Paul Sandland, Chief Financial Officer
e-mail:
corporate.enquiries@dechra.com
|
Office: +44 (0) 1606 814 730
|
|
|
|
|
TooleyStreet Communications Ltd
|
|
|
Fiona Tooley, Director
e-mail:
fiona@tooleystreet.com
|
Mobile: +44 (0) 7785 703 523
Office: +44 (0) 121 309 0099
|
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture, marketing, and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information, please visit:
www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
LEI: 213800J4UVB5OWG8VX82
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.
Forward Looking Statement
This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
